By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Kymriah
Miscellaneous antineoplastics

Kymriah

https://themeditary.com/drug/kymriah-8388.html
Medically Reviewed by Carmen Pope, BPharm TheMediTary.Com | Reviewed: Sep 05, 2023  Additional Content by TheMediTary.Com

Generic name: tisagenlecleucel [ tis-a-jen-lek-loo-sel ]

Drug class: Miscellaneous antineoplastics

Dosage form: intravenous suspension

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Tisagenlecleucel

Contents
Uses Warnings Before Taking Dosage Side effects Interactions
  • Kymriah (Tisagenlecleucel [ tis-a-jen-lek-loo-sel ])-genetically modified autologous T cells for infusion Kymriah genetically modified autologous T cells for infusion ()
  • Kymriah (Tisagenlecleucel [ tis-a-jen-lek-loo-sel ])-genetically modified autologous T cells for infusion Kymriah genetically modified autologous T cells for infusion ()
  • View all images

What is Kymriah?

Kymriah (tisagenlecleucel) is an individualized CAR-T cell therapy that may be used to treat:

  • Adults with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy (but not for patients with primary CNS lymphoma)
  • Adults with r/r follicular lymphoma (FL) after two or more lines of systemic therapy
  • Children and young adults up to and including 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant, or in second or later relapse.

Kymriah is an immune cellular therapy that only targets your B cells and B-cell precursors to help your immune system kill cancer cells. It is typically given as a single infusion after a short 4-day course of chemotherapy which prepares your body for the Kymriah infusion.

It is available only through a restricted program called the Kymriah Risk Evaluation and Mitigation Strategy (REMS). It must be ordered through a qualified Kymriah Treatment Center.

Kymriah was approved on August 30, 2017.

Warnings

Kymriah may cause a serious side effect called cytokine release syndrome, which causes fever, chills, trouble breathing, vomiting, and other symptoms, and can be potentially life-threatening. Your caregivers will have medication available to quickly treat this condition if it occurs.

It can also cause life-threatening nerve problems. Tell your caregivers or seek emergency medical attention if you have problems with speech, problems with thinking or memory, confusion, or a seizure.

Monitor for hypersensitivity reactions during the infusion.

Kymriah may cause serious infections. Monitor for signs and symptoms.

Other serious side effects include Grade 3 and above cytopenias, prolonged neutropenias, and hypogammaglobulinemias.

Secondary malignancies should be reported to Novartis Pharmaceuticals Corporation at 1-844-4Kymriah.

Do not drive, operate machinery or partake in hazardous tasks for at least 8 weeks after receiving Kymriah.

How should I use Kymriah

The dosage of Kymriah varies depending on the condition being treated and the age of the patient.

For at least 4 weeks, plan to stay near the hospital or clinic where you received Kymriah. Avoid being so far away that it takes you longer than 2 hours to travel back to the hospital.

Serious and sometimes fatal infections may develop after the injection. Call your doctor right away if you have a fever, chills, easy bruising, unusual bleeding, or other signs of infection.

Your doctor will consider premedication with acetaminophen and diphenhydramine or another H1-antihistamine approximately 30 to 60 minutes before infusion. Avoid using corticosteroids at any time except in the case of a life-threatening emergency.

Adults with r/r diffuse large B-cell lymphoma or follicular lymphoma

  • Administer 0.6 to 6.0 x 108 CAR-positive viable T-cells intravenously

May be suspended in one to three patient-specific infusion bags for IV administration.

B-cell precursor ALL

  • Above 50kg: Administer 0.1 to 2.5 x 108 total CAR-positive viable T-cells (non-weight based) intravenously
  • 50kg or less: Administer 0.2 to 5.0 x 106 CAR-positive viable T-cells per kg body weight intravenously

May be suspended in one to three patient-specific infusion bags for IV administration.

Detailed Kymriah dosage information
Kymriah Dosage information (more detail)

Before Taking

To make sure Kymriah is safe for you, tell your doctor if you have ever had:

  • hepatitis B or C;
  • HIV (human immunodeficiency virus); or
  • if you have received a vaccine in the past 2 weeks.

Women may need pregnancy testing before receiving this medicine. You may also need birth control to prevent pregnancy during and shortly after treatment with Kymriah and chemotherapy.

If you receive Kymriah during pregnancy, your baby's blood may need to be tested after it is born. This is to evaluate any effects the medicine may have had on the baby.

It may not be safe to breastfeed while using Kymriah. Ask your doctor about any risks.

Kymriah pregnancy and breastfeeding warnings (more detail)

What happens if I miss a dose?

Call your doctor for instructions if you miss any of your chemotherapy treatment, or if you miss a dose of your premedications to prevent side effects of Kymriah.

What happens if I overdose?

Since this medicine is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

What should I avoid while using Kymriah?

This medicine can cause weakness, drowsiness, confusion, problems with memory or coordination, and seizures. Avoid driving or operating machinery for at least 8 weeks after you are treated with Kymriah.

Do not donate blood, an organ, or any tissues or cells from your own body.

Do not receive a "live" vaccine while using Kymriah, or you could develop a serious infection. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.

Kymriah side effects

Kymriah may cause hypersensitivity reactions. Get emergency medical help if you have signs of an allergic reaction such as hives; difficulty breathing; or swelling of your face, lips, tongue, or throat.

A serious side effect of Kymriah is called cytokine release syndrome (CRS). Tell your caregivers right away if you have signs of this condition: fever, chills, trouble breathing, body aches, vomiting, diarrhea, or feeling light-headed. Your caregivers will have medication available to quickly treat CRS if it occurs.

Also, tell your caregivers or seek emergency medical attention if you have signs of life-threatening nerve problems: problems with speech, problems with thinking or memory, confusion, or a seizure.

This medicine can cause you to have a false positive screening test for HIV (human immunodeficiency virus). Tell any doctor who treats you that you are using Kymriah.

Using Kymriah may increase your risk of developing other types of cancer, or causing your leukemia to come back. Your doctor will need to check your progress for the rest of your life.

If you have ever had hepatitis B, Kymriah can cause this condition to come back or get worse. You will need frequent blood tests to check your liver function during treatment and for several months after you stop using this medicine.

Also, call your doctor at once if you have:

  • agitation
  • anxiety
  • bleeding or bruises
  • headaches
  • signs of infection - fever, chills, flu symptoms, mouth sores, skin sores, easy bruising or bleeding, cough, trouble breathing
  • tremors
  • trouble speaking or understanding what is said to you
  • unusual thoughts or behavior
  • unusual tiredness.

Common Kymriah side effects may include:

  • bleeding
  • cough
  • decreased appetite
  • edema
  • encephalopathy
  • fast heartbeats
  • fatigue
  • fever
  • gastrointestinal effects, such as nausea, vomiting, diarrhea, loss of appetite
  • headache, confusion, feeling tired
  • infections
  • low blood pressure
  • musculoskeletal pain
  • nausea and vomiting.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See more: Kymriah Side Effects

What other drugs will affect Kymriah?

Other drugs may interact with tisagenlecleucel, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

More about Kymriah (Tisagenlecleucel [ tis-a-jen-lek-loo-sel ])

Dosage information
Kymriah Side Effects
During pregnancy
Kymriah Prescribing Information
Drug images
Side effects
Drug class: Miscellaneous antineoplastics

Related treatment guides

Acute Lymphoblastic Leukemia
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by